JP2024534384A5 - - Google Patents
Info
- Publication number
- JP2024534384A5 JP2024534384A5 JP2024516560A JP2024516560A JP2024534384A5 JP 2024534384 A5 JP2024534384 A5 JP 2024534384A5 JP 2024516560 A JP2024516560 A JP 2024516560A JP 2024516560 A JP2024516560 A JP 2024516560A JP 2024534384 A5 JP2024534384 A5 JP 2024534384A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202113262 | 2021-09-16 | ||
| GB2113262.6 | 2021-09-16 | ||
| GB2206357.2 | 2022-04-29 | ||
| GBGB2206357.2A GB202206357D0 (en) | 2022-04-29 | 2022-04-29 | Treatment of cervical dystonia |
| PCT/GB2022/052361 WO2023041934A1 (en) | 2021-09-16 | 2022-09-16 | Modified bont/a for use in the treatment of cervical dystonia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534384A JP2024534384A (ja) | 2024-09-20 |
| JPWO2023041934A5 JPWO2023041934A5 (https=) | 2025-09-25 |
| JP2024534384A5 true JP2024534384A5 (https=) | 2025-09-25 |
Family
ID=83457513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516560A Pending JP2024534384A (ja) | 2021-09-16 | 2022-09-16 | 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250129354A1 (https=) |
| EP (1) | EP4401759B1 (https=) |
| JP (1) | JP2024534384A (https=) |
| KR (1) | KR20240067070A (https=) |
| CN (1) | CN121534167A (https=) |
| AU (1) | AU2022348206A1 (https=) |
| CA (1) | CA3231083A1 (https=) |
| FI (1) | FI4401759T3 (https=) |
| MA (1) | MA66538B1 (https=) |
| WO (1) | WO2023041934A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202206353D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| WO2025093844A1 (en) * | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| CA2758274C (en) | 2009-04-14 | 2018-04-10 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| EP3162894B1 (en) | 2011-05-19 | 2024-01-10 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| SG10201606666XA (en) | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2022
- 2022-09-16 JP JP2024516560A patent/JP2024534384A/ja active Pending
- 2022-09-16 FI FIEP22777691.1T patent/FI4401759T3/fi active
- 2022-09-16 WO PCT/GB2022/052361 patent/WO2023041934A1/en not_active Ceased
- 2022-09-16 KR KR1020247008446A patent/KR20240067070A/ko active Pending
- 2022-09-16 CN CN202511951407.7A patent/CN121534167A/zh active Pending
- 2022-09-16 MA MA66538A patent/MA66538B1/fr unknown
- 2022-09-16 AU AU2022348206A patent/AU2022348206A1/en active Pending
- 2022-09-16 US US18/690,378 patent/US20250129354A1/en active Pending
- 2022-09-16 CA CA3231083A patent/CA3231083A1/en active Pending
- 2022-09-16 EP EP22777691.1A patent/EP4401759B1/en active Active